AB Science Announces Initiation Of A New Phase 3 Study In Oncology With Masitinib In Patients With Metastatic Colorectal Cancer
Published: Dec 03, 2013
PARIS, Dec. 2, 2013 (GLOBE NEWSWIRE) -- AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specialized in research, development and marketing of protein kinase inhibitors (PKIs), announces the initiation of a phase 3 study to evaluate the safety and efficacy of masitinib in combination with FOLFIRI in patients with metastatic colorectal cancer (mCRC) in first relapse.
Help employers find you! Check out all the jobs and post your resume.